A team of researchers from the University of Houston and St. Luke’s Episcopal Hospital are working to develop improved screening methods to detect a potentially lethal, drug-resistant superbug that has made its way to Texas.
Chiesi Farmaceutici and NiKem Research have announced details of their extended research collaboration within the respiratory therapeutic area. The current extension involves the period 2011 to 2014 through a multimillion multi-FTE-based service agreement on pre-clinical projects of interest for Chiesi in the repiratory therapeutic area focused on pathologies such as asthma and COPD.
Scientists at Yale University have developed the first practical method to create a compound called huperzine A in the laboratory. The compound, which occurs naturally in a species of moss found in China, is an enzyme inhibitor that has been used to treat Alzheimer's disease in China since the late 1990s and is sold in the U.S. as a dietary supplement to help maintain memory.
Cresset and Redx Pharma announced that they have signed a major drug discovery collaboration, which gives Redx Pharma access to Cresset's computational chemistry technologies for use on their portfolio of drug discovery programs.
In a new study, University of Wisconsin-Madison researchers have described a simple process to separate sugars from a carrier molecule, then attach them to a drug or other chemical.
It is helpful—even life-saving—to have a warning sign before a structural system fails, but, when the system is only a few nanometers in size, having a sign that's easy to read is a challenge. Now, thanks to scientists from the University of Pennsylvania and Duke University, such warning can come in the form of a simple color change.
A team of Swinburne University of Technology researchers has shown that low-temperature microwaves can be used to open up pores in bacterial cells, which could lead to significant improvements in the design of drug delivery systems.
In an advance that could broadly expand the possible applications for microparticles, Massachusetts Institute of Technology engineers have developed a way to make microparticles of nearly any shape, using a micromold that changes shape in response to temperature.
The last century has seen two major pandemics caused by the H1N1 virus—the Spanish flu in 1918 and the swine flu scare of 2009. But scientists did not know what distinguished the swine flu from ordinary influenza in pigs or seasonal outbreaks in humans, giving it the power to travel extensively and infect large populations. Until now.
Most bacterial infections can be treated with antibiotics such as penicillin. However, such drugs are useless against viral infections. Now, in a development that could transform how viral infections are treated, a team of researchers at the Massachusetts Institute of Technology's Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
An international team of researchers has shown a derivative of a common culinary spice found in Indian curries could offer a new treatment hope for sufferers of the painful condition tendinitis.
Researchers at the California Institute of Technology have applied a relatively simple engineering technique to boost the battling prowess of an algae-sourced protein, called cyanovirin-N, that has gained attention for its antiviral properties.
The University of Michigan's Consortium for Stem Cell Therapies has achieved another of its primary goals: reprogramming adult skin cells so they behave like embryonic stem cells. The reprogrammed cells are called induced pluripotent stem cells, or iPs cells.
LEUKOCARE AG, a privately-owned specialist company for protein stabilization and biological surface coating, announced the signing of a cooperation agreement with Sanofi Pasteur, the vaccines division of Sanofi. As part of this cooperation, Sanofi Pasteur will explore LEUKOCARE’s SPS platform technology to enhance the shelf-life of selected vaccine formulations.
The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol fighter Lipitor and blood thinner Plavix. Generic competition will decimate sales of the brand-name drugs and cut costs to patients and companies that provide health benefits.
Researchers at Duke University Medical Center have discovered a way to block the damaging actions of chlamydia. The team, which included Duke University microbiologists and chemists, designed a molecule that takes away the bacteria's self-defense mechanisms.
The Siemens Healthcare Diagnostics D-dimer assay for the company's Stratus CS Acute Care Diagnostic System has been cleared by the FDA to exclude pulmonary embolism in conjunction with a non-high clinical pretest probability assessment model in point-of-care.
A study involving researchers at Caltech points to the possibility of using neutralizing antibodies in the development of a vaccine for HIV. Their research describes a group of novel antibodies that were isolated from HIV-infected individuals using a new cloning approach.
A breakthrough in sensing at Rice University could make finding signs of Alzheimer's disease nearly as simple as switching on a light. The technique should help researchers design better medications to treat the devastating disease.
Researchers at the Georgia Institute of Technology have designed a multiple-compartment gel capsule that could be used to simultaneously deliver drugs of different types. The researchers used a simple one-pot method to prepare the hydrogel capsules, which measure less than one micron.
Researchers have identified a protein long known to regulate gene expression as a potent suppressor of breast cancer growth. Their study is the first to demonstrate how this protein, known as Runx3, accomplishes this feat.
By accounting for the floppy, fickle nature of RNA, researchers at the Univ. of Michigan and the Univ. of California, Irvine have developed a new way to search for drugs that target this important molecule.
Compounds that act as natural antifreeze are used for protecting drugs, food and tissues. One common type of cryoprotectant features osmolyte molecules. Researchers have found that larger osmolytes are better at protecting proteins than smaller ones. The results could have major implications for the pharmaceutical industry, which loses product to the freezing process.
Troubled proteins in need of rescue may someday have a champion in a common drug used to treat high blood pressure. Rice Univ. research suggests lacidipine, a calcium channel blocker also known by brand names Lacipil and Motens, could be a key to helping people who suffer from an incurable, neuropathic form of Gaucher disease.
Ever since HIV was revealed as the infectious agent behind the AIDS epidemic, scientists have been striving to develop a vaccine against the disease. However, the task has proven difficult, because HIV mutates so rapidly. In a new finding that may allow vaccine designers to sidestep part of that obstacle, researchers at the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard Univ. have identified sections of an HIV protein where mutations would actually undermine the virus’ ability to survive and reproduce.